drugset
Drugs / taspoglutide
last change Mar 2011 re-read 9 days ago

taspoglutide

also known as BIM51077 · R1583 · RO5073031 · Taspoglutida

Peptide targets GLP1R via activation

Developed for
type 2 diabetes mellitus
Investigated by
Hoffmann-La Roche

Trials 13

today NCT01018173 · Ph 3 NCT01051011 · Ph 3 NCT00909597 · Ph 3 NCT00823992 · Ph 3 NCT00809705 · Ph 3 NCT00811460 · Ph 1 NCT00755287 · Ph 3 NCT00754988 · Ph 3 NCT00744367 · Ph 3 NCT00744926 · Ph 3 NCT00717457 · Ph 3 NCT00460941 · Ph 2 NCT00423501 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00811460 Nov 2008 → Aug 2009 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 22 trials · 1 met primary
Phase 2 NCT00460941 Apr 2007 → Jan 2008 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00423501 Feb → Nov 2007 type 2 diabetes mellitus Hoffmann-La Roche Completed Met primary
Phase 310 trials · 2 met primary
Phase 3 NCT01018173 Jan 2010 → Jan 2011 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT01051011 Jan → Dec 2010 type 2 diabetes mellitus Hoffmann-La Roche Terminated No outcome recorded
Phase 3 NCT00909597 May 2009 → Nov 2010 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00823992 Jan 2009 → May 2010 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00809705 Dec 2008 → Oct 2009 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00755287 Nov 2008 → Dec 2010 type 2 diabetes mellitus Hoffmann-La Roche Completed Met primary
Phase 3 NCT00754988 Oct 2008 → Mar 2011 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00744367 Oct 2008 → Nov 2010 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00744926 Aug 2008 → Apr 2010 type 2 diabetes mellitus Hoffmann-La Roche Completed No outcome recorded
Phase 3 NCT00717457 Jul 2008 → Mar 2011 type 2 diabetes mellitus Hoffmann-La Roche Completed Met primary

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as taspoglutide “Drug: taspoglutide” NCT01051011 ↗
12

NCT00755287 ↗

NCT00754988 ↗

NCT00823992 ↗

NCT00717457 ↗

NCT01018173 ↗

NCT00811460 ↗

NCT00909597 ↗

NCT00744367 ↗

NCT00744926 ↗

NCT00460941 ↗

Show 2 more sources
Known as BIM51077 “OBJECTIVE: To evaluate the efficacy and safety of taspoglutide (R1583/BIM51077), a human once-weekly glucagon-like peptide-1 analog, in patients with type 2 diabetes...” PMID 19366970 ↗ Apr 2009
Known as R1583 “OBJECTIVE: To evaluate the efficacy and safety of taspoglutide (R1583/BIM51077), a human once-weekly glucagon-like peptide-1 analog, in patients with type 2 diabetes...” PMID 19366970 ↗ Apr 2009
Known as RO5073031 “Taspoglutide (RO5073031) on Cardiovascular Outcomes” NCT01018173 ↗
Known as Taspoglutida ChEMBL registry synonym — accepted as the source's own label CHEMBL2107860 ↗
Action Activate “Glucagon-like peptide 1 receptor agonist” CHEMBL2107860 ↗
Modality Peptide “a human once-weekly glucagon-like peptide-1 analog” PMID 19366970 ↗ Apr 2009
Route Subcutaneous “double-blind subcutaneous treatment with placebo or taspoglutide” PMID 19366970 ↗ Apr 2009
Target GLP1R “Glucagon-like peptide 1 receptor agonist” CHEMBL2107860 ↗